The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
暂无分享,去创建一个
R. Labianca | J. Meyerhardt | M. Buyse | A. Shields | A. Grothey | J. Taieb | T. Maughan | T. Yoshino | A. Cervantes | T. André | A. Sobrero | J. Douillard | T. Iveson | I. Souglakos
[1] T. Yamanaka,et al. LBA24Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration , 2017 .
[2] M. Ychou,et al. 473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results , 2017 .
[3] J. Tabernero,et al. Updated results of the SCOT study : An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer , 2017 .
[4] R. Labianca,et al. LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) , 2017 .
[5] R. Labianca,et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. , 2017 .
[6] R. Labianca,et al. FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial. , 2017 .
[7] S. Barni,et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] F. D. De Braud,et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] N. Staff,et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Labianca,et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] D. Shibata,et al. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors , 2013, Supportive Care in Cancer.
[12] V. Lemmens,et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Kopec,et al. Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01 , 2012, Cancer.
[14] J. Cassidy,et al. Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study , 2011, Trials.
[15] M. Buyse,et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Cella,et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study , 2006, International Journal of Gynecologic Cancer.
[17] M. Leandri,et al. Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up , 2006, European Neurology.
[18] Markus Abt,et al. Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.
[19] T. Hickish,et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.